Synthesis and biological evaluation of novel SN38-glucose conjugate for colorectal cancer treatment

• Published in: Bioorganic & medicinal chemistry letters 2023-02, Vol.81, p.129128-129128, Article 129128
• Main Authors: Zhang, Ruiming, Luo, Yi, Du, Chenghao, Wu, Ling, Wang, Yankang, Chen, Yuanduan, Li, Shouqian, Jiang, Xin, Xie, Yongmei
• Format: Article
• Language: English
• Subjects: 7-Ethyl-10-hydroxycamptothecin; Animals; Antineoplastic Agents, Phytogenic - therapeutic use; Antitumor activity; Camptothecin; Camptothecin - pharmacology; Cell Line, Tumor; Colorectal cancer; Colorectal Neoplasms - drug therapy; Disease Models, Animal; Drug Delivery Systems; Humans; Irinotecan - pharmacology; Prodrug
• ISSN: 0960-894X; 1464-3405
• DOI: 10.1016/j.bmcl.2023.129128

[Display omitted] 7-Ethyl-10-hydroxycamptothecin (SN38), the bioactive metabolite of irinotecan (CPT-11), has been shown to be 100–1000 times more effective than CPT-11. However, the poor water solubility and bioavailability of SN38 constrained its clinical application. In this study, we synthesized a novel SN38-glucose conjugate (FSY04) to address this issue. Our in vitro studies indicated that FSY04 had a potent inhibitory ability against colorectal cancer (CRC) cell lines of SW-480 and HCT-116 compared to the inhibitory capacity of CPT-11. Interestingly, FSY04 possessed lower cytotoxicity against normal cell lines of LO2 and 293T in contrast with CPT-11. Moreover, FSY04 is more active than CPT-11 in inducing apoptosis, inhibiting migration, and invasion. In vivo experiments suggested that half of the equivalent of FSY04 inhibited the growth of SW480 in the xenograft tumor model better than one equivalent of CPT-11. Our data demonstrated FSY04 to be a promising agent in CRC therapy.